» Articles » PMID: 2301287

Rapid Analysis of Lymphocyte Subsets in Cord Blood

Overview
Specialty Pathology
Date 1990 Feb 1
PMID 2301287
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Several investigators have enumerated cellular populations in neonatal cord blood with variable results. In this study, the authors established reference ranges for lymphocyte subsets in cord blood from healthy newborns using a whole blood lysis technique on the Coulter Immunoprep Epics Leukocyte Preparation System (Coulter Immunology, Hialeah, FL). All analyses were performed on a flow cytometer by gating on forward angle versus 90 degrees light scatter. Lymphocytes demonstrated all surface markers examined, including T4, T8, T3, T11, B1, NKH-1, I3, and 4B4; 2H4 suppressor inducer lymphocytes were prominent in neonatal blood. The authors think this standardized system may be suitable for use in neonatal and pediatric patients because it quickly processes small aliquots of whole blood with minimal sample manipulation.

Citing Articles

Novel gene manipulation approaches to unlock the existing bottlenecks of CAR-NK cell therapy.

Dehghan F, Metanat Y, Askarizadeh M, Ahmadi E, Moradi V Front Cell Dev Biol. 2025; 12:1511931.

PMID: 40007761 PMC: 11850336. DOI: 10.3389/fcell.2024.1511931.


Current landscape of clinical use of ex vivo expanded natural killer cells for cancer therapy.

Azevedo J, Godoy J, Souza C, Sielski M, Coa L, Barbosa Junior A Einstein (Sao Paulo). 2024; 22:eRW0612.

PMID: 39661859 PMC: 11634336. DOI: 10.31744/einstein_journal/2024RW0612.


Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside.

Zhang B, Yang M, Zhang W, Liu N, Wang D, Jing L Cell Death Dis. 2024; 15(1):50.

PMID: 38221520 PMC: 10788349. DOI: 10.1038/s41419-024-06438-7.


Chimeric antigen receptor engineered natural killer cells for cancer therapy.

Zhang Y, Zhou W, Yang J, Yang J, Wang W Exp Hematol Oncol. 2023; 12(1):70.

PMID: 37563648 PMC: 10413722. DOI: 10.1186/s40164-023-00431-0.


Manipulating NK cellular therapy from cancer to invasive fungal infection: promises and challenges.

Oh B, Chan L, Chai L Front Immunol. 2023; 13:1044946.

PMID: 36969979 PMC: 10034767. DOI: 10.3389/fimmu.2022.1044946.